Stayble Therapeutics | Media - Stayble Therapeutics

Latest press releases

April 17, 2024 Regulatorisk

(SV) Stayble Therapeutics publicerar årsredovisningen för 2023

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2023. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.

April 15, 2024 Regulatorisk

(SV) Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 15 maj 2024 kl. 13.00 på bolagets kontor på Lennart Torstenssonsgatan 8 i Göteborg. Inregistrering till årsstämman påbörjas kl. 12.30.

April 3, 2024

Abstract on STA363’s clinical effect on disc volume has been accepted for presentation at an important congress

Stayble Therapeutics AB (“Stayble” or the “Company”) announces that the Company’s scientific abstract regarding the treatment concept for herniated discs has been accepted for a poster presentation at the International Society for the Study of the Lumbar Spine (ISSLS) annual meeting in Milan, Italy, on 27-31 May 2024.

March 5, 2024

All patients included in Stayble Therapeutics’ phase Ib study in disc hernia with STA363

Stayble Therapeutics AB (“Stayble” or the “Company”) announces today that the last patient has been included in the ongoing phase Ib clinical study with STA363 towards disc hernia. No significant side effects have so far been reported and currently, none of the included patients has discontinued their participation in the study. Results from the study are expected to be available in Q4 2024.